Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0033774 (pruritus)
 14,546 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Staphylococci and beta-haemolytic streptococci are usually responsible for causing common primary and secondary skin infections. Mupirocin (Bactroban, Eismycin; trademarks of Beecham Group plc), a new antibiotic unrelated to any other antibacterial agent and developed for topical use only, shows a high level of activity against these bacteria. In an open multicentre study the efficacy and safety of mupirocin (2% in a polyethylene glycol vehicle) was evaluated in 1,391 general practice patients with superficial skin infections. The most common skin infections treated were pyoderma (eg, impetigo, folliculitis) and secondarily infected skin lesions. Treatment consisted of application of the ointment three times daily for an average of nine days. A total of 1,304 patients were evaluable for post-treatment clinical assessment. At the end of the treatment 961 (73.7 per cent) patients were cured and in 293 (22.5 per cent) patients the symptoms of the infection had markedly improved. In total, 525 bacterial strains were isolated from the wounds of 445 patients, predominantly staphylococci (n = 344) and streptococci (n = 93). Local side effects such as burning, itching and reddening were observed in 39 (2.9 per cent) of 1,357 patients. No evidence of systemic toxicity or abnormal laboratory data was noted. Mupirocin 2% ointment proved to be effective and safe in the treatment of primary and secondary skin infections.
 ...
PMID:Efficacy and safety of 2% mupirocin ointment in the treatment of primary and secondary skin infections--an open multicentre trial. 251 63

The pharmacology, pharmacokinetics, clinical efficacy, adverse effects, and dosage and administration of mupirocin are reviewed. Mupirocin is a naturally occurring antibiotic produced by submerged fermentation of Pseudomonas fluorescens. It inhibits bacterial protein synthesis by binding reversibly and specifically to isoleucyl-tRNA synthetase. Organisms resistant to other antimicrobials are not simultaneously resistant to mupirocin. Mupirocin is highly active against Staphylococcus aureus and other staphylococci and streptococci. When mupirocin ointment is applied topically, local concentrations exceed the inhibitory concentrations for staphylococci and remain detectable for up to 72 hours. Placebo-controlled studies demonstrate the ability of mupirocin to eliminate nasal carriage of S. aureus in health care workers. Observational studies suggest that mupirocin is efficacious in treating methicillin-resistant S. aureus (MRSA) outbreaks. Preliminary studies show that mupirocin might have a role in preventing infections in high-risk patients. Although mupirocin seems to be well tolerated, mild to moderate adverse events have been reported, including respiratory problems and effects confined to the nose--erythema, swelling, burning or stinging, pruritus, and dryness. Mupirocin calcium ointment has FDA-approved labeling for the eradication of nasal MRSA colonization in adult patients and health care workers as part of comprehensive infection-control programs to reduce the risk of infection during institutional outbreaks. The recommended dosage is 0.5 g inserted into each nostril twice daily for five days. Intranasal mupirocin ointment appears to be a useful addition to infection-control programs designed to reduce the risk of infection among patients during MRSA outbreaks.
 ...
PMID:Intranasal mupirocin for outbreaks of methicillin-resistant Staphylococcus aureus. 933 38